Fulcrum Therapeutics Inc(FULC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.21 | Insider Own | 3.37% | Shs Outstand | 76.3M | Perf Week | 0.82% |
| Market Cap | 0.28B | Forward P/E | - | EPS next Y | 79.78% | Insider Trans | 18.4% | Shs Float | 73.7M | Perf Month | 0.82% |
| Enterprise Value | -0.03B | PEG | - | EPS next Q | -0.07 | Inst Own | 102.21% | Short Float | 9.16% | Perf Quarter | - |
| Income | -0.09B | P/S | - | EPS this Y | 48.94% | Inst Trans | -9.6% | Short Ratio | 4.31 | Perf Half Y | -49.59% |
| Sales | 0.00B | P/B | 0.91 | EPS next 5Y | 63.32% | ROA | -30.75% | Short Interest | 6.76M | Perf YTD | -67.2% |
| Book/sh | 4.07 | P/C | 0.89 | EPS past 3/5Y | 21.49% 15.8% | ROE | -32.38% | 52W High | -76.43% ($15.74) | Perf Year | -56.86% |
| Cash/sh | 4.18 | P/FCF | - | Sales past 3/5Y | - | ROIC | -27.12% | 52W Low | 31.1% ($2.83) | Perf 3Y | 10.75% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 0.04% | Gross Margin | - | Volatility(W/M) | 2.21% 1.84% | Perf 5Y | -83.24% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.07 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 31.35 | EPS Q/Q | -24.16% | Profit Margin | - | RSI (14) | 48.8 | Recom | 4 |
| Dividend Gr. 3/5Y | - | Current Ratio | 31.35 | Sales Q/Q | - | SMA20 | 0.19% ($3.7) | Beta | 2.82 | Target Price | $4 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/08/05 | SMA50 | -1.36% ($3.76) | Rel Volume | 0.6 | Prev Close | $3.77 |
| Employees | 55 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -33.07% - | SMA200 | -36.73% ($5.86) | Avg Volume(3M) | 1.57M | Price | $3.71 |
| IPO | 2019/7/18 | Option/Short | Yes/Yes | Trades | 2698 | Volume | 933,221 | Change | -1.59% |
🧬 Fulcrum Therapeutics (FULC) is a US-based clinical-stage biotech company that has been researching treatments for rare diseases using gene expression regulation technology. Following the discontinuation of its key clinical programs, the company is now reviewing strategic alternatives, with its cash holdings serving as the primary driver of its enterprise value.
Over the past 1 year, on the lower side
76% below its 1-year high.
Traded less than usual. That is 60% of its average volume.
FULC has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +48.9% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Sell.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -83.2%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 102.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #269 of 597 in the industry
Based on market cap of $283M.
SCTX#267 Scribe Therapeutics Inc $292M PER - 
EIKN#268 Eikon Therapeutics Inc $288M PER - FULC#269 Fulcrum Therapeutics Inc $283M PER - 
VCRE#270 Vicore Pharma Holding AB ADR $276M PER - 
LYEL#271 Lyell Immunopharma Inc $271M PER - 
FAQ
What kind of company is FULC?
FULC belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of FULC?
The market cap of FULC is approximately $283M, ranking 3,697 within its sector.
What is the 52-week high and low for FULC?
FULC has recorded a 52-week high of $15.74 and a low of $2.83.
